The human T cell leukemic/lymphotropic virus type 1 (HTLV-1), discovered several years ago, is the causative agent for a rapid progressive haematological malignancy, adult T cell leukemia (ATL), for debilitating neurological diseases and for a number of inflammatory based diseases. Although the heterogeneous features of the diseases caused by HTLV-1, a common topic concerning related therapeutic treatments relies on the use of antiretrovirals. This review will compare the different approaches and opinions in this matter, giving a concise overview of preclinical as well as clinical studies covering all the aspects of antiretrovirals in HTLV-1 infection. Studies will be grouped on the basis of the class of antiretroviral, putting together both pre-clinical and clinical results and generally following a chronological order. Analysis of the existing literature highlights that a number of preclinical studies clearly demonstrate that different classes of antiretrovirals, already utilized as anti-HIV agents, are actually capable to efficiently contrast HTLV-1 infection. Nevertheless, the results of most of the clinical studies are generally discouraging on the same point. In conclusion, the design of new antiretrovirals more specifically focused on HTLV-1 targets, and/or the establishment of early treatments with antiretrovirals could hopefully change the perspectives of diseases caused by HTLV-1.

Marino-Merlo, F., Balestrieri, E., Matteucci, C., Mastino, A., Grelli, S., Macchi, B. (2020). Antiretroviral Therapy in HTLV-1 Infection: An Updated Overview. PATHOGENS, 9(5), 342 [10.3390/pathogens9050342].

Antiretroviral Therapy in HTLV-1 Infection: An Updated Overview

Balestrieri, Emanuela;Matteucci, Claudia;Grelli, Sandro;Macchi, Beatrice
2020

Abstract

The human T cell leukemic/lymphotropic virus type 1 (HTLV-1), discovered several years ago, is the causative agent for a rapid progressive haematological malignancy, adult T cell leukemia (ATL), for debilitating neurological diseases and for a number of inflammatory based diseases. Although the heterogeneous features of the diseases caused by HTLV-1, a common topic concerning related therapeutic treatments relies on the use of antiretrovirals. This review will compare the different approaches and opinions in this matter, giving a concise overview of preclinical as well as clinical studies covering all the aspects of antiretrovirals in HTLV-1 infection. Studies will be grouped on the basis of the class of antiretroviral, putting together both pre-clinical and clinical results and generally following a chronological order. Analysis of the existing literature highlights that a number of preclinical studies clearly demonstrate that different classes of antiretrovirals, already utilized as anti-HIV agents, are actually capable to efficiently contrast HTLV-1 infection. Nevertheless, the results of most of the clinical studies are generally discouraging on the same point. In conclusion, the design of new antiretrovirals more specifically focused on HTLV-1 targets, and/or the establishment of early treatments with antiretrovirals could hopefully change the perspectives of diseases caused by HTLV-1.
Pubblicato
Rilevanza internazionale
Recensione
Esperti anonimi
Settore CHIM/08 - Chimica Farmaceutica
Settore MED/07
English
ATL
HAM/TSP
HTLV-1
antiretrovirals
Marino-Merlo, F., Balestrieri, E., Matteucci, C., Mastino, A., Grelli, S., Macchi, B. (2020). Antiretroviral Therapy in HTLV-1 Infection: An Updated Overview. PATHOGENS, 9(5), 342 [10.3390/pathogens9050342].
Marino-Merlo, F; Balestrieri, E; Matteucci, C; Mastino, A; Grelli, S; Macchi, B
Articolo su rivista
File in questo prodotto:
File Dimensione Formato  
pathogens-09-00342.pdf

accesso aperto

Descrizione: articolo su rivista
Tipologia: Versione Editoriale (PDF)
Licenza: Copyright dell'editore
Dimensione 715.25 kB
Formato Adobe PDF
715.25 kB Adobe PDF Visualizza/Apri

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/2108/252904
Citazioni
  • ???jsp.display-item.citation.pmc??? 12
  • Scopus 13
  • ???jsp.display-item.citation.isi??? 13
social impact